Bearbmagovva

Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer

Furkejuvvon:
Publikašuvnnas:NPJ Breast Cancer vol. 10, no. 1 (2024), p. 28
Váldodahkki: Morganti, Stefania
Eará dahkkit: Jin, Qingchun, Vincuilla, Julie, Buehler, Ryan, Ryan, Sean, Stokes, Samantha, Parker, Tonia, Mittendorf, Elizabeth A., King, Tari A., Weiss, Anna, Partridge, Ann H., Bychkovsky, Brittany L., Curigliano, Giuseppe, Tayob, Nabihah, Lin, Nancy U., Garber, Judy E., Tolaney, Sara M., Lynce, Filipa
Almmustuhtton:
Nature Publishing Group
Fáttát:
Genetic testing
Oncology
Tumors
Surgery
Cancer therapies
Chemotherapy
Breast cancer
Liŋkkat:Citation/Abstract
Full Text - PDF
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

MARC

LEADER 00000nab a2200000uu 4500
001 3039629899
003 UK-CbPIL
022 |a 2374-4677 
024 7 |a 10.1038/s41523-024-00632-8  |2 doi 
035 |a 3039629899 
045 2 |b d20240101  |b d20241231 
084 |a 274865  |2 nlm 
100 1 |a Morganti, Stefania  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Broad Institute of MIT and Harvard, Boston, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623) 
245 1 |a Clinicopathological characteristics and eligibility for adjuvant olaparib of germline <i>BRCA1/2</i> mutation carriers with HER2-negative early breast cancer 
260 |b Nature Publishing Group  |c 2024 
513 |a Journal Article 
520 3 |a Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated. In this study, we sought to characterize the real-world proportion of gBRCA1/2 PV carriers eligible for adjuvant olaparib according to the OlympiA criteria, and to compare clinicopathologic characteristics and outcomes between eligible and ineligible patients. 
653 |a Genetic testing 
653 |a Oncology 
653 |a Tumors 
653 |a Surgery 
653 |a Cancer therapies 
653 |a Chemotherapy 
653 |a Breast cancer 
700 1 |a Jin, Qingchun  |u Dana-Farber Cancer Institute, Department of Data Science, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Vincuilla, Julie  |u Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896) 
700 1 |a Buehler, Ryan  |u Dana-Farber Cancer Institute, Division of Cancer Genetics and Prevention, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Ryan, Sean  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896) 
700 1 |a Stokes, Samantha  |u Broad Institute of MIT and Harvard, Boston, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623) 
700 1 |a Parker, Tonia  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896) 
700 1 |a Mittendorf, Elizabeth A.  |u Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital, Division of Breast Surgery, Department of Surgery, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294) 
700 1 |a King, Tari A.  |u Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital, Division of Breast Surgery, Department of Surgery, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294) 
700 1 |a Weiss, Anna  |u Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital, Division of Breast Surgery, Department of Surgery, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); University of Rochester Medical Center, Division of Surgical Oncology, Rochester, USA (GRID:grid.412750.5) (ISNI:0000 0004 1936 9166) 
700 1 |a Partridge, Ann H.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
700 1 |a Bychkovsky, Brittany L.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana-Farber Cancer Institute, Division of Cancer Genetics and Prevention, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Curigliano, Giuseppe  |u University of Milan, Department of Oncology and Hemato-Oncology, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822); European Institute of Oncology IRCCS, Milan, Italy (GRID:grid.15667.33) (ISNI:0000 0004 1757 0843) 
700 1 |a Tayob, Nabihah  |u Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana-Farber Cancer Institute, Department of Data Science, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Lin, Nancy U.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
700 1 |a Garber, Judy E.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana-Farber Cancer Institute, Division of Cancer Genetics and Prevention, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Tolaney, Sara M.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
700 1 |a Lynce, Filipa  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
773 0 |t NPJ Breast Cancer  |g vol. 10, no. 1 (2024), p. 28 
786 0 |d ProQuest  |t Health & Medical Collection 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/3039629899/abstract/embedded/J7RWLIQ9I3C9JK51?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/3039629899/fulltextPDF/embedded/J7RWLIQ9I3C9JK51?source=fedsrch